Drug Shortage Report for TEVA-BUPROPION XL

Last updated on 2020-02-13 History
Report ID 68577
Drug Identification Number 02439662
Brand name ACT BUPROPION XL
Common or Proper name BUPROPION XL
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) BUPROPION HYDROCHLORIDE
Strength(s) 300MG
Dosage form(s) TABLET (EXTENDED-RELEASE)
Route of administration ORAL
Packaging size 500
ATC code N06AX
ATC description ANTIDEPRESSANTS
Reason for shortage Delay in shipping of the drug.
Anticipated start date
Actual start date 2018-12-01
Estimated end date 2020-02-29
Actual end date 2020-02-12
Shortage status Resolved
Updated date 2020-02-13
Company comments Allocating inventory to support regular demand. Cannot support increased demand for this molecule, as well as now delays in releases from the mfg site.
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v30 2020-02-13 French Compare
v29 2020-02-13 English Compare
v28 2020-01-17 French Compare
v27 2020-01-17 English Compare
v26 2019-12-19 French Compare
v25 2019-12-19 English Compare
v24 2019-12-12 French Compare
v23 2019-12-12 English Compare
v22 2019-12-05 French Compare
v21 2019-12-05 English Compare
v20 2019-10-03 French Compare
v19 2019-10-03 English Compare
v18 2019-09-19 French Compare
v17 2019-09-19 English Compare
v16 2019-09-10 French Compare
v15 2019-09-10 English Compare
v14 2019-09-10 French Compare
v13 2019-09-10 English Compare
v12 2019-09-10 French Compare
v11 2019-09-10 English Compare

Showing 1 to 20 of 30